Skip to main content
AmigoFish

Episode 200: Immune Checkpoint Inhibitors

From Core EM - Emergency Medicine Podcast ·

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

https://coreem.net/podcast/episode-200-immune-checkpoint-inhibitors/

We discuss a new class of medications, Immune Checkpoint Inhibitors, and their side effects.

Hosts:

Avir Mitra, MD

Brian Gilberti, MD

https://media.blubrry.com/coreem/content.blubrry.com/coreem/Immune_Checkpoint_Inhibitors.mp3

Download (https://media.blubrry.com/coreem/content.blubrry.com/coreem/Immune_Checkpoint_Inhibitors.mp3)

Leave a Comment (https://coreem.net/podcast/episode-200-immune-checkpoint-inhibitors/#comments)

Tags: Oncology (https://coreem.net/tag/oncology/)

Show Notes

Overview of Immune Checkpoint Inhibitors (ICIs)

- ICIs are a relatively new class of oncologic drugs that have revolutionized cancer treatment.

- Unlike chemotherapy, ICIs help the immune system develop memory against cancer cells and adapt as the cancer mutates.

- Since their release in 2011, ICIs have expanded to 83 indications for 17 different cancers, with approximately 230,000 patients using them.

Mechanism of Action

- Cancer cells can evade the immune system by binding to T cell receptors that downregulate the immune response.

- ICIs work by blocking these receptors or ligands, preventing the downregulation and allowing T cells to proliferate and attack cancer cells.

- Common ICIs

Risks and Toxicities of ICIs

- ICIs can lead to autoimmune attacks on healthy cells due to immune system upregulation.

- Immune-related adverse effects (irAEs) include colitis, pneumonitis, dermatitis, hepatitis, and endocrine issues (e.g., hypothyroid, hypocortisolemia, hypophysitis).

- These toxicities can present as infections, making diagnosis challenging in the emergency room.

Management of ICI Toxicities in the ER

- Diagnosis: Look for signs that mimic infections (e.g., cough and fever in pneumonitis).

- Diagnostic Imaging in pneumonitis: If CXR is normal but suspicion is high, consider CT scans to differentiate conditions like pneumonitis from other issues such as malignancy-associated pleural effusion or acute pulmonary embolism.

- Treatment: The primary treatment for irAEs is steroids (e.g., prednisone 1 mg/kg). Start steroids early and hold the ICI to manage symptoms effectively and increase the likelihood of resuming ICI therapy later.

- Consider using antibiotics in combination with steroids if there is uncertainty about whether symptoms are due to infection or ICI toxicity.

- Coordinate care with the patient’s oncologist if possible

Disposition Decisions

- Patient disposition (admit vs. discharge) should depend on clinical presentation and severity.

- Coordination with oncology is crucial; they are often comfortable with starting steroids even if there is a potential infection.

- Patients can be discharged if symptoms are mild, but sicker patients with more complex presentations may require admission.

Take-Home Points

- ICIs are a new class of cancer drugs that effectively target cancer cells but come with unique immune-related toxicities.

- Diagnosing irAEs can be challenging due to symptom overlap with infections.

- The cornerstone of treatment is early administration of steroids and temporarily holding the ICI.

- Close collaboration with oncology teams is essential for optimal patient management.

Read More (https://coreem.net/podcast/episode-200-immune-checkpoint-inhibitors/)

Back to Core EM - Emergency Medicine Podcast · Report a problem